Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP InhibitorsRetrospective Study · 2021 · 97 citations
2Genomics of lethal prostate cancer at diagnosis and castration resistanceOriginal Research · 2019 · 320 citations
3Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate CancerCohort Study · 2013 · 871 citations
4DNA-Repair Defects and Olaparib in Metastatic Prostate CancerOriginal Research · 2015 · 2,199 citations
5Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> MutationOriginal Research · 2017 · 3,412 citations
6Olaparib for Metastatic Castration-Resistant Prostate CancerOriginal Research · 2020 · 2,318 citations
7Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerOriginal Research · 2020 · 820 citations
8Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialOriginal Research · 2021 · 164 citations
9Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT TrialJournal of Clinical Oncology · 2026
10Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister StudyJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Northwestern University